Vanda seeking FDA commissioner review of Hetlioz generics decision
In 2023, Vanda filed citizen petitions challenging the FDA's approval of two generic versions of Vanda's drug Hetlioz, and in July 2025, outgoing CDER director Corrigan-Curay sided with the prior decision to approve these generic versions.